Mayne Pharms losses is only due to management issues otherwise their revenue is big enough to sustain a viable company , with Salisbury facility and CDM alone able to generate more than 50 m in revenue . now with less shares on sale and after we see the impact of DTC and Nexstellis relaunch across 50 states . we should be able to see a steady revenue increase across 50 states in the us . buy back wouldn't have been initiated if it was going to put the company at risk of insolvency . they obviously had more cash on hand and forecat +ve cash contribution in the 1HFY24 . The market price is not always a measure and in particular with more than %80 retail investors . for example retail investors have put up BRN share price to $2.00 whilst having to revenue and many other penny stocks . with mayne pharma after research at least if the company sold you will get double ur share price 7.60 per share and so it os an undervalued share . obviosuly vibrinium and goldman scahs they have investment research teams and they don't just buy any stock
MYX Price at posting:
$3.27 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)